RXI Pharmaceuticals Corp (NASDAQ:RXII) has announced that the company will currently be undergoing the process of appointing a new leading Oncology expert to the company’s scientific advisory board.
This follows the light to the news that the company is expected to make lead presentations at upcoming leader investor and healthcare conferences.
More details about the company’s new leading Oncology expert
The company announced that they were appointing Dr. Rolf Kiessling, as the company’s new Oncology expert. This is believed to be a good fit for the company, as Kiessling, already serves as a Senior Chief Physician Of Radiumhemmet at Karolinska Hospital.
When questioned on this matter, Kiessling stated, “I welcome the opportunity to work with the accomplished team of advisors at RXi and look forward to being a part of their mission to develop innovative therapeutics to improve patients lives.”
Kiessling himself is somewhat of an innovative physician, which could have a substantial positive impact on RXi Pharmaceuticals. He is credited with the discovery of Natural Killer cells, (NK Cells). Furthermore, he has over 250 publications to his name.
Upcoming presentations that are expected from RXi
It was also recently announced that following the appointment of Kiessling, the company is also expected to present at two high-ranked upcoming healthcare related conferences. The first of which is scheduled to take place on February, 14, and the latter on February, 16.
The presentations themselves, regard an overview of the company, which will include details relating to the company’s RNAi delivery system, as well as various development projects, which the company plans to tackle in this coming financial year.
These presentations may be troublesome, however, they can provide potential opportunities for the company, as these are classified as premier events. Often, those who attend these presentations are either high-end leaders in the industry or large potential investors, which can have a positive impact on the business.